novel
coronaviru
offici
known
sever
acut
respiratori
syndrom
coronaviru
etiolog
agent
corona
viru
diseas
emerg
wuhan
hubei
provinc
china
march
world
health
organ
declar
diseas
pandem
chines
centr
diseas
control
prevent
show
increas
mortal
peopl
diabet
vs
overal
vs
patient
diabet
respect
report
case
peopl
diabet
may
need
special
attent
clinic
care
absenc
known
effici
therapi
situat
publichealth
emerg
mani
drug
tri
recent
treatment
includ
lowcost
antimalari
drug
chloroquin
deriv
hydroxychloroquin
hcq
along
sever
antivir
drug
hcq
approv
treatment
type
diabet
india
sinc
thirdor
fourthlin
drug
would
interest
research
impact
patient
diabet
infect
report
gather
far
suggest
number
drug
could
potenti
candid
treatment
although
clinic
effect
drug
yet
fulli
evalu
list
drug
summar
tabl
review
articl
systemat
search
medic
data
base
collat
avail
evid
emerg
far
efficaci
chloroquin
hydroxychloroquin
treatment
patient
covid
without
diabet
present
perspect
compound
addit
also
pool
current
ongo
trial
compound
systemat
search
pubm
databas
till
march
use
key
word
chloroquin
hydroxychloroquin
retriev
total
articl
two
articl
written
chines
exclud
addit
also
access
retriev
full
text
cross
refer
import
articl
written
english
moreov
also
access
current
ongo
trial
compound
clinicaltrialsgov
experiment
studi
suggest
chloroquin
proven
antimalari
drug
capabl
inhibit
replic
sever
intracellular
microorgan
includ
coronavirus
vitro
also
believ
chloroquin
may
vari
mechan
action
may
differ
depend
upon
pathogen
studi
increasingli
learnt
antivir
antiinflammatori
activ
chloroquin
may
role
treatment
patient
novel
chloroquin
increas
endosom
ph
interfer
glycosyl
cellular
receptor
sarscov
therebi
potenti
block
viral
infect
addit
chloroquin
also
inhibit
quinon
involv
sialic
acid
biosynthesi
acid
monosaccharid
cell
transmembran
protein
requir
ligand
recognit
make
agent
broad
antivir
agent
import
note
human
coronaviru
orthomyxovirus
use
sialic
acid
moieti
receptor
moreov
chloroquin
chang
ph
lysosom
like
inhibit
cathepsin
lead
format
autophagosom
cleav
spike
protein
furthermor
chloroquin
inhibit
mapkinas
interfer
molecular
crosstalk
besid
alter
virion
assembl
bud
interf
proteolyt
process
protein
previou
experiment
studi
also
demonstr
chloroquin
potent
effect
vitro
primarili
attribut
deficit
glycosyl
receptor
viru
cell
surfac
bind
angiotensinconvert
enzym
express
lung
heart
kidney
intestin
sinc
util
similar
surfac
receptor
believ
chloroquin
also
interfer
receptor
glycosyl
thu
prevent
attach
target
cell
chines
research
studi
effect
chloroquin
vitro
use
vero
cell
line
infect
found
chloroquin
highli
effect
reduc
viral
replic
easili
achiev
standard
dose
due
favor
penetr
tissu
includ
lung
sinc
structur
mechan
action
chloroquin
hydroxychloroquin
hcq
exactli
except
addit
hydroxi
moieti
one
termin
hcq
act
weak
base
chang
ph
acid
intracellular
organel
includ
endosomeslysosom
essenti
membran
fusion
believ
agent
could
effect
tool
howev
import
question
still
remain
whether
hcq
similar
effect
infect
data
show
hcq
effect
inhibit
entri
transport
postentri
stage
similar
chloroquin
one
studi
found
hcq
potent
agent
chloroquin
inhibit
vitro
addit
hcq
act
effect
intracellular
bacteri
infect
coxiella
burnetii
q
fever
tropheryma
whipplei
whippl
diseas
addit
hydroxyl
molecul
make
hcq
less
permeabl
bloodretin
barrier
allow
faster
clearanc
retin
pigment
cell
therebi
suggest
lesser
risk
retin
toxic
hcq
compar
chloroquin
furthermor
narrow
therapeut
safeti
index
margin
chloroquin
make
hcq
safer
option
chloroquin
addit
issu
consid
sever
sick
patient
cytokin
storm
associ
diseas
sever
signific
decreas
product
proinflammatori
marker
cytokin
hcq
made
agent
success
diseas
modifi
antiinflammatori
agent
treatment
variou
autoimmun
diseas
includ
rheumatoid
arthriti
system
lupu
erythematosu
sjogren
syndrom
longterm
clinic
safeti
profil
hcq
better
chloroquin
allow
higher
daili
dose
hcq
less
drugdrug
interact
antivir
antiinflammatori
action
chloroquin
led
numer
trial
urgent
face
global
health
emerg
chines
studi
involv
patient
found
chloroquin
superior
control
group
reduc
symptom
durat
exacerb
pneumonia
includ
radiolog
improv
promot
virusneg
seroconvers
without
sever
side
effect
repres
first
human
trial
ever
conduct
chloroquin
although
detail
result
trial
yet
publish
avail
letter
form
interestingli
earli
result
led
china
includ
chloroquin
prevent
treatment
pneumonia
moreov
nation
health
commiss
peopl
republ
china
recommend
inclus
chloroquin
next
version
guidelin
prevent
diagnosi
treatment
pneumonia
caus
studi
chloroquin
given
dose
mg
chloroquin
twice
daili
mild
sever
pneumonia
see
tabl
second
human
studi
current
avail
conduct
hcq
openlabel
nonrandom
trial
n
conduct
marseil
franc
gautret
et
al
found
hcq
alon
combin
hcq
plu
azithromycin
highli
significantli
effect
clear
viral
nasopharyng
carriag
measur
polymeras
chain
reaction
pcr
threeto
six
day
subject
compar
control
virolog
clearanc
postinclus
primari
outcom
hcq
vs
control
versu
respect
p
addit
virolog
clearanc
postinclus
hcq
plu
azithromycin
hcq
control
arm
respect
p
data
suggest
synergist
effect
azithromycin
hcq
inde
azithromycin
shown
antivir
effect
zika
ebola
virus
vitro
studi
howev
yet
known
whether
action
well
result
convert
potenti
carrier
seroneg
patient
import
regard
prevent
commun
transmiss
sinc
data
wuhan
china
show
patient
carrier
long
day
usual
around
day
result
studi
encourag
context
convert
patient
seroneg
subject
within
day
interestingli
studi
also
show
effect
hcq
significantli
higher
p
symptomat
patient
compar
asymptomat
patient
author
acknowledg
limit
studi
small
sampl
size
dropout
six
patient
limit
followup
apart
nonrandom
openlabel
natur
trial
close
look
studi
also
suggest
cycl
threshold
ct
valu
nasopharyng
swab
pcr
call
sampl
neg
lower
ct
valu
deem
neg
viru
compar
convent
ct
threshold
ct
defin
number
cycl
run
pcr
test
turn
posit
word
lower
number
ct
denot
viru
present
lesser
number
cycl
requir
hit
threshold
moreov
nasopharyng
swab
pcr
less
sensit
tool
compar
pcr
bronchoalveolar
lavag
sputum
furthermor
exclus
five
patient
receiv
hcq
overal
analysi
exagger
final
result
studi
nevertheless
base
limit
avail
evid
date
given
prevail
pandem
institut
organ
alreadi
recogn
util
chloroquin
hcq
expert
consensu
depart
scienc
technolog
health
commiss
guangdong
provinc
publish
februari
base
vitro
evid
still
unpublish
clinic
experi
chloroquin
phosphat
tablet
dose
mg
twice
per
day
day
patient
diagnos
mild
moder
sever
case
pneumonia
absenc
contraind
drug
central
clinic
task
forc
korea
treat
case
recommend
use
lopinavir
mg
bid
chloroquin
mg
oral
per
day
hydroxychloroquin
mg
oral
per
day
day
moder
sever
case
similarli
dutch
center
diseas
control
public
document
websit
also
suggest
use
chloroquin
sever
infect
admit
intens
care
unit
tabl
summar
recommend
dose
variou
group
antivir
activ
chloroquin
hcq
identifi
vitro
studi
growth
mani
differ
virus
inhibit
cell
cultur
line
agent
includ
sar
coronaviru
mice
studi
also
demonstr
activ
agent
human
coronaviru
enteroviru
zika
viru
influenza
howev
benefit
chloroquin
seen
prevent
influenza
dengu
infect
random
doubleblind
placebocontrol
clinic
trial
similarli
chloroquin
activ
ex
vivo
studi
vivo
studi
ebolaviru
nipah
influenza
virus
data
chloroquin
chikungunya
viru
even
intrigu
chloroquin
satisfactori
antivir
activ
chikungunya
vitro
anim
studi
show
increas
viru
replic
aggrav
fever
incomplet
viral
clearanc
human
trial
chloroquin
show
improv
chikungunya
acut
ill
rather
increas
chronic
arthralgia
observ
postil
period
compar
control
role
chloroquin
human
immunodefici
viru
inconclus
viral
diseas
chloroquin
modestli
effect
far
era
chronic
hepat
c
suggest
increas
virolog
respons
pegyl
interferon
plu
ribavirin
therefor
result
chloroquin
hcq
far
done
promis
previou
trial
viral
diseas
moreov
drug
low
cost
reason
safe
see
wide
avail
countri
malaria
endem
expectedli
precaut
need
use
drug
includ
frequent
monitor
hematolog
paramet
rbc
wbc
platelet
count
measur
serum
electrolyt
blood
glucos
hypoglycem
potenti
hcq
hepat
well
renal
function
sinc
drug
potenti
prolong
qtc
routin
electrocardiographi
essenti
prior
start
drug
coadministr
drug
known
prolong
qtc
interv
antiarrhythm
antidepress
antipsychot
antihistamin
teneligliptin
ondansetron
moxifloxacin
etc
must
avoid
moreov
addit
azithromycin
hcq
done
french
trial
gautret
et
al
may
increas
risk
qtc
prolong
perform
ecg
daili
qtc
msec
addit
hypoglycemia
must
look
patient
diabet
especi
concurr
use
chloroquinehcq
lopinavirritonavir
chloroquin
hcq
use
concurr
lopinavirritonavir
remdisivir
anticip
qtc
prolong
final
pharmacovigil
visual
mental
disturb
also
close
requir
although
sporad
case
report
chloroquineinduc
cardiomyopathi
revers
heart
failur
literatur
mani
studi
larg
metaanalysi
conduct
patient
rheumatoid
arthriti
point
reduc
cardiovascular
risk
compound
nevertheless
sinc
drug
potenti
prolog
qtc
baselin
ecg
done
patient
establish
cardiovascular
diseas
clinician
use
drug
must
know
contraind
compound
hypersensit
agent
retinopathi
porphyria
epilepsi
preexist
maculopathi
defici
recent
myocardi
infarct
qtc
msec
chloroquin
contraind
pregnanc
tabl
avail
guidelin
treatment
chloroquin
hydroxychloroquin
hydroxychloroquin
mg
tid
day
odonc
daili
bidtwic
daili
tidthric
daili
urtiupp
respiratori
tract
infect
pcrpolymeras
chain
reaction
iv
intraven
although
evid
chloroquin
hcq
limit
base
experiment
data
two
small
human
trial
consid
potenti
favor
benefitrisk
balanc
chloroquin
hcq
absenc
valid
treatment
option
believ
treatment
could
use
current
context
pandem
outbreak
summar
current
consider
propos
line
manag
tabl
low
cost
chloroquin
hcq
could
also
effect
strategi
counter
especi
patient
diabet
comorbid
mortal
high
resourc
constrain
overburden
heath
care
system
middleand
lowincom
counti
includ
india
herebi
declar
conflict
interest
relat
tabl
base
avail
evid
far
includ
vitro
ex
vivo
vivo
studi
e
experiment
two
human
studi
consid
benefitrisk
ratio
well
low
cost
chloroquin
hydroxychloroquin
indian
context
propos
follow
regim
evid
avail
propos
chemoprophylaxi
conclus
evid
far
howev
chloroquin
hcq
could
research
prophylact
agent
endem
area
recent
guidelin
indian
council
medic
research
recommend
prophylact
agent
see
refer
indic
dose
note
hcq
use
adjunct
control
glycemia
adult
patient
type
diabet
approv
treatment
india
howev
role
adjunct
treatment
test
potenti
role
prophylaxi
diabet
research
could
attempt
view
consid
higher
mortal
patient
diabet
compar
nondiabet
subject
confirm
chloroquin
phosphat
urti
mg
bid
day
lrti
mg
bid
day
b
hydroxychloroquin
load
dose
mg
bid
day
mainten
dose
mg
bid
day
c
monitor
watch
side
effect
watch
hypoglycemia
diabet
especi
concurr
use
lopinavirritonavir
use
concurr
lopinavirritonavir
remdisivir
due
increas
qtc
prolong
complet
blood
count
renal
hepat
profil
ecg
e
watch
qtc
prolong
urtiupp
respiratori
tract
infect
lrtilow
respiratori
tract
infect
hcqhydroxychloroquin
bid
e
twice
daili
